Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm	Not yet recruiting	Phase 2	2026-08-12		NCT07301424

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Amgen	180
University of Alberta	249

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University of Alberta	Edmonton	Canada	11

Clinical trials